MNPR-101

MNPR-101 is a novel humanized monoclonal antibody that targets the urokinase plasminogen activator receptor (uPAR), a protein overexpressed on the surface of various tumor cells. By binding to uPAR—particularly its D2D3 domain—MNPR-101 can be used as both a therapeutic and diagnostic agent. It has been developed into radiopharmaceutical forms such as MNPR-101-Lu (conjugated with lutetium‑177 for therapy) and MNPR‑101‑Zr (conjugated with zirconium‑89 for PET imaging). The drug is being investigated primarily in advanced solid tumors including pancreatic, ovarian, triple negative breast, colorectal, bladder, lung and stomach cancers. Its mechanism involves selective targeting of uPAR to deliver cytotoxic agents or radioisotopes directly to cancer cells while sparing healthy tissue[1][2][3][4][5][6][8].